(redirected from Interleukin-17)
Also found in: Dictionary, Medical, Encyclopedia.
Related to Interleukin-17: IL-17F
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to interleukin

any of several lymphokines that promote macrophages and killer T cells and B cells and other components of the immune system

Related Words

References in periodicals archive ?
Housseau, "Interleukin-17 and type 17 helper T cells in cancer management and research," ImmunoTargets and Therapy, no.
Wahl, "Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis," The American Journal of Pathology, vol.
Kcs: Keratinocytes IL-23: Interleukin-23 IL-17: Interleukin-17 [A.sub.3]AR: A3 adenosine receptor PBMCs: Peripheral blood mononuclear cells RA: Rheumatoid arthritis NF-[kappa]B: Nuclear factor kappa B CREB: cAMP response element-binding protein TNF-[alpha]: Tumor necrosis a PI3K: Phosphoinositide 3-kinase.
Jin, "Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis," Cytokine, 2015.
Gaffen, "Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease," Immunology, vol.
Although there is no consensus on the role of interleukin-17 in the pathogenesis of HS, studies by Matusiak et al.
Kasayama et al., "Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members," Journal of Biological Chemistry, vol.
Linden, "Interleukin-17 family members and inflammation," Immunity, vol.
Verhoeven et al., "Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut," Nature Medicine, vol.
Efficacy and safety of interleukin-17 antagonists in patients with plague psoriasis: a meta analysis from phase 3 randomized controlled trails.
Th17 cells can produce interleukin-17 (IL-17) and play a pro-inflammatory role that has been linked to pregnancy failure.
The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis.
In February 2017, the US Food and Drug Administration approved the Biologics License Application for Siliq, a novel human monoclonal antibody that binds to the interleukin-17 (IL-17) receptor A and inhibits inflammatory signaling by preventing the binding of several types of IL-17 to the receptor.
This treatment, part of a class of medicines called interleukin-17 (IL-17) inhibitors, is the first of its kind to be recommended by NICE.